<DOC>
	<DOCNO>NCT00675259</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , paclitaxel albumin-stabilized nanoparticle formulation carboplatin , work different way stop growth tumor cell , either kill cell stop dividing . Monoclonal antibody , bevacizumab , block tumor growth different way . Some find tumor cell help kill carry tumor-killing substance . Others interfere ability tumor cell grow spread . Bevacizumab may also stop growth breast cancer block blood flow tumor . Giving combination chemotherapy together bevacizumab surgery may make tumor small reduce amount normal tissue need remove . Giving bevacizumab surgery may kill tumor cell remain surgery . PURPOSE : This phase II trial study side effect well give paclitaxel albumin-stabilized nanoparticle formulation carboplatin together bevacizumab work treat woman undergo surgery stage II stage III breast cancer .</brief_summary>
	<brief_title>Phase II NCT ( Neoadjuvant Chemotherapy ) w/ Weekly Abraxane Combination With Carboplatin &amp; Bevacizumab Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - To determine complete pathological response ( pCR ) breast/axillary lymph node woman stage II III breast cancer treat neoadjuvant therapy comprise paclitaxel albumin-stabilized nanoparticle formulation , carboplatin , bevacizumab follow surgery adjuvant bevacizumab . - To determine side effect regimen patient . Secondary - To evaluate dynamic contrast-enhanced magnetic resonance image assess pCR . - To measure LZTS1 gene expression neoadjuvant therapy evaluate whether LZTS1 gene expression correlate pCR . - To evaluate feasibility toxicity adjuvant bevacizumab administer 6 month . OUTLINE : - Neoadjuvant therapy : Patients receive paclitaxel albumin-stabilized nanoparticle formulation IV 30 minute carboplatin IV 30 minute day 1 , 8 , 15 bevacizumab IV 30-90 minute day 1 15 . Treatment repeat every 28 day 5 course . After completion course 5 , patient receive paclitaxel albumin-stabilized nanoparticle formulation IV 30 minute carboplatin IV 30 minute day 1 , 8 , 15 . Patients proceed surgery . - Surgery : Approximately 4-5 week completion neoadjuvant therapy , patient undergo definitive surgery ( either lumpectomy mastectomy ) . Patients node-positive disease inflammatory breast cancer baseline also undergo axillary lymph node dissection . Patients proceed adjuvant therapy . - Adjuvant therapy : Beginning approximately 6 week surgery , patient receive bevacizumab IV 30-90 minute every 3 week 6 month . Patients hormone receptor-positive disease also receive endocrine therapy . Patients may also receive additional adjuvant chemotherapy radiotherapy discretion treat physician . Patients undergo dynamic contrast-enhanced magnetic resonance imaging baseline , course 2 neoadjuvant therapy , completion neoadjuvant therapy ( prior definitive surgery ) assessment tumor response . Tumor tissue collect baseline surgery correlative laboratory study . LZST1 gene expression assess immunohistochemistry neoadjuvant therapy .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Inclusion : Histologically confirm breast cancer Clinically radiographically measurable residual tumor core biopsy Eastern Cooperative Oncology Group ( ECOG ) performance status 01 Age ≥18 yr Absolute neutrophil count ≥ 1,500/mm³ Hemoglobin ≥ 9 g/dL Platelet count ≥ 100,000/ mm³ Creatinine ≤ 1.5 time upper limit normal ( ULN ) Urine protein : creatinine ratio &lt; 1.0 AST ( aspartate aminotransferase ) ALT ≤ 2.5 time ULN Alkaline phosphatase ≤ 2.5 time ULN Bilirubin normal Women childbearing potential must use effective contraception Left ventricular ejection fraction ( LVEF ) normal echocardiogram MUGA Exclusion : No residual tumor initial biopsy Peripheral neuropathy grade 2 high HER2 neu overexpression either IHC 3+ FISH+ No history prior treatment breast cancer . No history unstable angina myocardial infarction within past 12 month Pregnant nursing woman Anticoagulation therapy within last 6 month History gastrointestinal bleeding Recent hemoptysis No known hepatitis B HIV seropositivity No inadequately control hypertension , define systolic blood pressure ( BP ) &gt; 150 mm Hg and/or diastolic BP &gt; 100 mm Hg despite antihypertensive medication History hypertensive crisis hypertensive encephalopathy New York Heart Association class IIIV congestive heart failure History stroke transient ischemic attack time Significant vascular disease ( e.g. , aortic aneurysm aortic dissection ) No symptomatic peripheral vascular disease Evidence bleed diathesis coagulopathy Significant traumatic injury within past 28 day History abdominal fistula , gastrointestinal perforation , intraabdominal abscess within past 6 month Serious , nonhealing wound , ulcer , bone fracture Known hypersensitivity component bevacizumab</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>stage II breast cancer</keyword>
	<keyword>stage IIIA breast cancer</keyword>
	<keyword>stage IIIB breast cancer</keyword>
	<keyword>stage IIIC breast cancer</keyword>
</DOC>